Literature DB >> 22489047

Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation.

Pankaj R Daga1, Nurulain T Zaveri.   

Abstract

The opioid receptor-like receptor, also known as the nociceptin receptor (NOP), is a class A G protein-coupled receptor (GPCR) in the opioid receptor family. Although NOP shares a significant homology with the other opioid receptors, it does not bind known opioid ligands and has been shown to have a distinct mechanism of activation compared to the closely related opioid receptors mu, delta, and kappa. Previously reported homology models of the NOP receptor, based on the inactive-state GPCR crystal structures, give limited information on the activation and selectivity features of this fourth member of the opioid receptor family. We report here the first active-state homology model of the NOP receptor based on the opsin GPCR crystal structure. An inactive-state homology model of NOP was also built using a multiple template approach. Molecular dynamics simulation of the active-state NOP model and comparison to the inactive-state model suggest that NOP activation involves movements of transmembrane (TM)3 and TM6 and several activation microswitches, consistent with GPCR activation. Docking of the selective nonpeptidic NOP agonist ligand Ro 64-6198 into the active-state model reveals active-site residues in NOP that play a role in the high selectivity of this ligand for NOP over the other opioid receptors. Docking the shortest active fragment of endogenous agonist nociceptin/orphaninFQ (residues 1-13) shows that the NOP extracellular loop 2 (EL2) loop interacts with the positively charged residues (8-13) of N/OFQ. Both agonists show extensive polar interactions with residues at the extracellular end of the TM domain and EL2 loop, suggesting agonist-induced reorganization of polar networks, during receptor activation.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22489047      PMCID: PMC3393802          DOI: 10.1002/prot.24077

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  46 in total

1.  Sequence-structure homology recognition by iterative alignment refinement and comparative modeling.

Authors:  M G Williams; H Shirai; J Shi; H G Nagendra; J Mueller; K Mizuguchi; R N Miguel; S C Lovell; C A Innis; C M Deane; L Chen; N Campillo; D F Burke; T L Blundell; P I de Bakker
Journal:  Proteins       Date:  2001

2.  Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation.

Authors:  Marco Scarselli; Bo Li; Soo-Kyung Kim; Jürgen Wess
Journal:  J Biol Chem       Date:  2007-01-09       Impact factor: 5.157

3.  Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide.

Authors:  R Guerrini; G Calo; A Rizzi; C Bianchi; L H Lazarus; S Salvadori; P A Temussi; D Regoli
Journal:  J Med Chem       Date:  1997-06-06       Impact factor: 7.446

4.  Constitutive activation of the opioid receptor-like (ORL1) receptor by mutation of Asn133 to tryptophan in the third transmembrane region.

Authors:  Kenneth W L Kam; David C New; Yung H Wong
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

Review 5.  Knowledge-based prediction of protein structures and the design of novel molecules.

Authors:  T L Blundell; B L Sibanda; M J Sternberg; J M Thornton
Journal:  Nature       Date:  1987 Mar 26-Apr 1       Impact factor: 49.962

6.  Two mutations in extracellular loop 2 of the human GnRH receptor convert an antagonist to an agonist.

Authors:  Thomas R Ott; Brigitte E Troskie; Roger W Roeske; Nicola Illing; Colleen A Flanagan; Robert P Millar
Journal:  Mol Endocrinol       Date:  2002-05

7.  Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study.

Authors:  A Mansour; L P Taylor; J L Fine; R C Thompson; M T Hoversten; H I Mosberg; S J Watson; H Akil
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

8.  The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.

Authors:  Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

9.  Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors.

Authors:  Lucie P Pellissier; Jessica Sallander; Mercedes Campillo; Florence Gaven; Emilie Queffeulou; Marion Pillot; Aline Dumuis; Sylvie Claeysen; Joël Bockaert; Leonardo Pardo
Journal:  Mol Pharmacol       Date:  2009-01-23       Impact factor: 4.436

10.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.

Authors:  Guillaume Lebon; Tony Warne; Patricia C Edwards; Kirstie Bennett; Christopher J Langmead; Andrew G W Leslie; Christopher G Tate
Journal:  Nature       Date:  2011-05-18       Impact factor: 49.962

View more
  13 in total

1.  In silico study of the structurally similar ORL1 receptor agonist and antagonist pairs reveal possible mechanism of receptor activation.

Authors:  Milan Senćanski; Ljiljana Dosen-Mićović
Journal:  Protein J       Date:  2014-06       Impact factor: 2.371

2.  Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.

Authors:  Michael E Meyer; Arpit Doshi; Dennis Yasuda; Nurulain T Zaveri
Journal:  AAPS J       Date:  2021-05-11       Impact factor: 4.009

3.  A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Authors:  Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko
Journal:  Sci Transl Med       Date:  2018-08-29       Impact factor: 17.956

4.  Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13).

Authors:  Maria Camilla Cerlesi; Huiping Ding; Mark F Bird; Norikazu Kiguchi; Federica Ferrari; Davide Malfacini; Anna Rizzi; Chiara Ruzza; David G Lambert; Mei-Chuan Ko; Girolamo Calo; Remo Guerrini
Journal:  Eur J Pharmacol       Date:  2016-11-19       Impact factor: 4.432

Review 5.  Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.

Authors:  Norikazu Kiguchi; Huiping Ding; Shiroh Kishioka; Mei-Chuan Ko
Journal:  Curr Top Med Chem       Date:  2020       Impact factor: 3.295

Review 6.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Authors:  Ann P Lin; Mei-Chuan Ko
Journal:  ACS Chem Neurosci       Date:  2012-11-06       Impact factor: 4.418

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.

Authors:  Jianping Hu; Zhiwei Feng; Shifan Ma; Yu Zhang; Qin Tong; Mohammed Hamed Alqarni; Xiaojun Gou; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2016-05-26       Impact factor: 4.956

9.  Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.

Authors:  Pankaj R Daga; Willma E Polgar; Nurulain T Zaveri
Journal:  J Chem Inf Model       Date:  2014-09-17       Impact factor: 4.956

10.  Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands.

Authors:  Salvatore Pacifico; Alfonso Carotenuto; Diego Brancaccio; Ettore Novellino; Erika Marzola; Federica Ferrari; Maria Camilla Cerlesi; Claudio Trapella; Delia Preti; Severo Salvadori; Girolamo Calò; Remo Guerrini
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.